Nagai Tomonori, Okubo Takashi, Sakaguchi Riko, Seki Hiroyuki, Takeda Satoru
Department of Obstetrics and Gynecology, Saitama Medical Center, Saitama Medical School, Kawagoe-shi, Saitama, 350-8550, Japan.
Int J Clin Oncol. 2008 Dec;13(6):541-4. doi: 10.1007/s10147-008-0776-0. Epub 2008 Dec 18.
Described as a poorly differentiated adenosquamous cancer, glassy cell carcinoma of the uterine cervix is a rare disease considered to have an extremely poor prognosis. Saitama Medical Center has been offering neoadjuvant intraarterial chemotherapy (NAC) to cervical cancer patients as a means of avoiding postoperative radiation therapy, achieving downstaging, and improving prognosis. We report a patient with glassy cell carcinoma of the uterine cervix who responded to NAC, and we discuss this case with reference to reports in the literature. A 28-year-old gravida 1, para 0 patient was referred to the Department of Obstetrics and Gynecology at Saitama Medical Center for concurrent cervical cancer at 23.5 gestational weeks. The patient was admitted to our center following the diagnosis of stage IIb cervical cancer (glassy cell carcinoma), to await fetal development, and an elective cesarean section was performed at slightly more than 29 gestational weeks. Three cycles of NAC with carboplatin (CBDCA)/etoposide/epirubicin, started 3 days after the operation, shrank the tumor remarkably. An extended radical hysterectomy was subsequently performed. It has been 6 years, to date, since the initial treatment, and our patient is alive and disease/recurrence free.
子宫颈玻璃样细胞癌被描述为一种低分化腺鳞癌，是一种罕见疾病，其预后被认为极差。埼玉医疗中心一直为宫颈癌患者提供新辅助动脉内化疗（NAC），作为避免术后放疗、实现降期和改善预后的一种手段。我们报告了一例对NAC有反应的子宫颈玻璃样细胞癌患者，并结合文献报道对该病例进行讨论。一名28岁、孕1产0的患者在妊娠23.5周时因合并宫颈癌被转诊至埼玉医疗中心妇产科。该患者在被诊断为IIb期宫颈癌（玻璃样细胞癌）后入住我院，等待胎儿发育，在妊娠29周多一点时进行了择期剖宫产。术后3天开始进行三个周期的NAC，使用卡铂（CBDCA）/依托泊苷/表柔比星，肿瘤明显缩小。随后进行了扩大根治性子宫切除术。自初次治疗以来，至今已有6年，我们的患者仍然存活，无疾病/复发。
